Baxa Corporation announces its launch of the ValiMed System for medication safety at booth no. 2221 at the American Society of Health-System Pharmacists Midyear Meeting to be held December 4 – 8, 2005 in Las Vegas, Nev. The innovative ValiMed Technology offers validation of medication to ensure the type and strength of high-risk medications. The technology also validates narcotic returns and identifies counterfeit medications.
Englewood, Colo., November 29, 2005 – Baxa Corporation will introduce the ValiMed Medication Validation System at the 40th annual meeting of the American Society for Health-System Pharmacists. Over the course of the five-day meeting, Baxa representatives will demonstrate the new technology, designed to validate medication type and strength; detect counterfeit products for brand protection, and provide quality assurance for compounded products.
The ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patent-pending technology identifies the strength to validate compounded doses of high risk medications prior to dispensing. The ValiMed Device verifies medications in seconds, providing an added level of safety in the medication dispensing process. The system also assists with detection of narcotic loss and identification of counterfeit medications.
“The ValiMed Solution fits with Baxa Corporation's mission to offer our customers innovative fluid medication devices that improve operations and increase medication safety,” said Greg Baldwin, Baxa Chairman and CEO. “ValiMed is a great addition to our product lines,” he notes of the announcement.
At the meeting, Baxa representatives will be demonstrating the ValiMed System’s capabilities in their booth, number 2221. CDEX Inc., developer of the ValiMed Medication Validation System and other innovative substance detection and verification systems, is participating in the meeting as well in booth number 1021. Representatives of CDEX Inc. will be demonstrating the ValiMed System’s ability to distinguish authentic flu vaccines and Tamiflu®.
“The ValiMed System is ideally suited to address modern hospital pharmacy needs,” said Malcolm Philips, CDEX CEO and Chairman. “The technology allows pharmacists to ensure the accuracy of compounded solutions, meeting USP 797 and other regulatory requirements.” The ASHP launch spotlights the ValiMed technology for meeting medication accuracy and med error reduction goals.
Capabilities of the ValiMed Medication Validation System will be spotlighted in two poster sessions during the meeting: Improving medication safety: use of spectral medication validation in high risk intravenous medication (IV) compounding in a pediatric hospital pharmacy, based on experiences at the University of Michigan’s CS Mott Children’s Hospital (Monday, December 5, 2005; 2:00 PM) and Use of spectroscopy to enhance safety in IV compounding, James G. Stevenson PharmD, Director of Pharmacy Services, University of Michigan Health System (Wednesday, December 7, 2005; 3:00 PM).
For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency. Under an agreement announced in early November, Baxa is the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
About Baxa Corporation Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternative-site pharmacies. Privately held, Baxa Corporation has subsidiaries and offices in Canada, the United Kingdom and Denmark, and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc. CDEX Inc. (OTCBB: CEXI), is a technology development company focused on developing and marketing products using chemical detection and validation technologies. CDEX technology is focused currently on two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com and http://www.valimed.com.
For Baxa Corporation Marian Robinson, Vice President, Marketing Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Maggie Chamberlin Holben, APR Absolutely Public Relations: 303.984.9801 or 303.669.3558
For CDEX Brad Wills Wills PR: 301.346.7398
Any statements in this release that are not historical are essentially forward-looking. Forward-looking statements are subject to risks and uncertainties that cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Baxa Corporation and CDEX Inc. undertake no obligation to publicly update any forward-looking statements.
This press release was posted by the following PR Firm Absolutely Public Relations (View Listing in Directory of PR Firms)
Posts: 9 | Registered: Nov 2005
| IP: Logged |
University of Maryland Medical Center Partners with CDEX to Implement Medication Validation Solution; CDEX's ValiMed System Chosen by UMMS to Verify Compounded Medications and Doses, Validate Narcotic Returns, and Identify Counterfeit Pharmaceuticals 11/29/2005 10:00:08 AM
ROCKVILLE, Md. & BALTIMORE, Nov 29, 2005 (BUSINESS WIRE) -- The University of Maryland Medical Center has selected the CDEX (CEXI) ValiMed system to perform end product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The CDEX ValiMed medication verification system was developed to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded. The University of Maryland Medical Center (UMMC) is part of a private, not-for-profit organization that includes six hospitals and has more than 11,000 employees. The system provides a full range of primary and specialty care to people throughout Maryland and the Mid-Atlantic region. ValiMed will be installed at the University of Maryland Medical Center, a 655-bed teaching hospital.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"We are focused on patient safety at UMMC, and the CDEX ValiMed product offers us an additional opportunity to validate the end products being dispensed from the pharmacy and to validate returned narcotics," said Marc Summerfield, Director of Pharmacy at UMMC. "With ValiMed, we will have an added level of safety on certain products that we dispense every day, and added cost-effective audit capabilities for our controlled substances compliance initiatives."
"As the list of nationally-recognized healthcare providers using the ValiMed solution continues to grow, CDEX is particularly pleased that the University of Maryland Medical Center, a world-class hospital located in the same region where CDEX is headquartered, has selected this innovative, proven system for end-product medication testing and return narcotic validation," said Malcolm Philips, CEO and Chairman of the Board for CDEX.
The CDEX ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process.
About The University of Maryland Medical Center (UMMC)
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement*cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX, Inc.
CDEX, Inc. Brad Wills, 301-346-7398 bwills*wills-pr.com
Posts: 9 | Registered: Nov 2005
| IP: Logged |